Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05506332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 18, 2022 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
Trial Details
NCT Number NCT05506332
Lead Sponsor University Hospital, Antwerp
Conditions
(from sponsor)		 Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Related terms Leukemia, Myeloid, Acute
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov